JP2000501085A - 多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用 - Google Patents

多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用

Info

Publication number: JP2000501085A
Authority: JP; Japan
Prior art keywords: pentoxifylline; interferon; combination; administered; type
Prior art date: 1995-11-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP9520104A

Other languages

English (en)

Japanese (ja)

Inventor

リッケンマン，ピーター

Original Assignee

ドクターレンチュレーアルツナイミッテルゲーエムベーハーウントコー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-30

Filing date

1996-11-08

Publication date

2000-02-02

1996-11-08 Application filed by ドクターレンチュレーアルツナイミッテルゲーエムベーハーウントコー filed Critical ドクターレンチュレーアルツナイミッテルゲーエムベーハーウントコー

2000-02-02 Publication of JP2000501085A publication Critical patent/JP2000501085A/ja

Status Pending legal-status Critical Current

Links

BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 title claims abstract description 27
229960001476 pentoxifylline Drugs 0.000 title claims abstract description 27
102000002227 Interferon Type I Human genes 0.000 title claims abstract description 11
108010014726 Interferon Type I Proteins 0.000 title claims abstract description 11
201000006417 multiple sclerosis Diseases 0.000 title claims description 27
238000011282 treatment Methods 0.000 claims abstract description 15
239000012730 sustained-release form Substances 0.000 claims abstract description 11
238000013268 sustained release Methods 0.000 claims abstract description 7
238000007920 subcutaneous administration Methods 0.000 claims abstract description 6
238000007918 intramuscular administration Methods 0.000 claims abstract 3
206010053395 Progressive multiple sclerosis Diseases 0.000 claims abstract 2
108090000467 Interferon-beta Proteins 0.000 claims description 14
102000014150 Interferons Human genes 0.000 claims description 12
108010050904 Interferons Proteins 0.000 claims description 12
238000002347 injection Methods 0.000 claims description 10
239000007924 injection Substances 0.000 claims description 10
229940079322 interferon Drugs 0.000 claims description 10
102000006992 Interferon-alpha Human genes 0.000 claims description 6
108010047761 Interferon-alpha Proteins 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 6
239000003826 tablet Substances 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
238000004806 packaging method and process Methods 0.000 claims description 4
239000000243 solution Substances 0.000 claims description 4
102100026720 Interferon beta Human genes 0.000 claims description 3
239000003708 ampul Substances 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 2
239000003405 delayed action preparation Substances 0.000 claims 1
239000006186 oral dosage form Substances 0.000 claims 1
102000003996 Interferon-beta Human genes 0.000 description 11
230000000694 effects Effects 0.000 description 10
239000003814 drug Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
230000002195 synergetic effect Effects 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000016192 Demyelinating disease Diseases 0.000 description 3
206010012305 Demyelination Diseases 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000011284 combination treatment Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000005021 gait Effects 0.000 description 3
229960004584 methylprednisolone Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
208000006820 Arthralgia Diseases 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
208000005622 Gait Ataxia Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
238000012404 In vitro experiment Methods 0.000 description 2
108010005714 Interferon beta-1b Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
229940021459 betaseron Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
239000000945 filler Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000003908 liver function Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
UOQDKQOXSLQEOJ-UHFFFAOYSA-N 2-methylprop-2-enoate;trimethylazanium Chemical compound C[NH+](C)C.CC(=C)C([O-])=O UOQDKQOXSLQEOJ-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000003164 Diplopia Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000034347 Faecal incontinence Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010022004 Influenza like illness Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010027926 Monoplegia Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010040026 Sensory disturbance Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000002134 immunopathologic effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000004552 water soluble powder Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP9520104A 1995-11-30 1996-11-08 多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用 Pending JP2000501085A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19544768.9		1995-11-30
DE19544768A DE19544768C1 (de)	1995-11-30	1995-11-30	Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
PCT/EP1996/004906 WO1997019686A1 (de)	1995-11-30	1996-11-08	Verwendung einer kombination aus pentoxifyllin mit typ i-interferonen zur behandlung der multiplen sklerose

Publications (1)

Publication Number	Publication Date
JP2000501085A true JP2000501085A (ja)	2000-02-02

Family

ID=7778885

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9520104A Pending JP2000501085A (ja)	1995-11-30	1996-11-08	多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用

Country Status (7)

Country	Link
EP (1)	EP0863759A1 (de)
JP (1)	JP2000501085A (de)
CA (1)	CA2238770A1 (de)
DE (1)	DE19544768C1 (de)
HU (1)	HUP9903698A2 (de)
NO (1)	NO982463D0 (de)
WO (1)	WO1997019686A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP823999A0 (en) *	1999-01-20	1999-02-11	University Of Queensland, The	A treatment
WO2007041506A1 (en) *	2005-10-03	2007-04-12	Melior Discovery, Inc.	Purine formulations and methods for managing disorders
EP2265334A2 (de)	2008-02-29	2010-12-29	Concert Pharmaceuticals, Inc.	Substituierte xanthin-derivate
US20110053961A1 (en)	2009-02-27	2011-03-03	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
MX2012002704A (es)	2009-09-02	2012-03-21	Concert Pharmaceuticals Inc	Derivados de xantina sustituidos.
WO2012031138A2 (en)	2010-09-01	2012-03-08	Concert Pharmaceuticals, Inc.	Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
US20140296263A1 (en)	2011-07-19	2014-10-02	Concert Pharmaceuticals, Inc.	Substituted xanthine derivatives
JP2015512947A (ja)	2012-04-13	2015-04-30	コンサートファーマシューティカルズインコーポレイテッド	置換キサンチン誘導体
WO2013159006A1 (en)	2012-04-20	2013-10-24	Concert Pharmaceuticals, Inc.	Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
WO2015160913A1 (en)	2014-04-18	2015-10-22	Concert Pharmaceuticals, Inc.	Methods of treating hyperglycemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU538186B2 (en) *	1980-03-07	1984-08-02	Scotia Holdings Plc	Prostaglandin precursors
US5668117A (en) *	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5763446A (en) *	1992-03-26	1998-06-09	University Of Southern California	Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
GB9218810D0 (en) *	1992-09-04	1992-10-21	Univ Birmingham	Antiviral pyrimidine nucleosides
DE4343034C1 (de) *	1993-12-16	1995-06-08	Rentschler Arzneimittel	Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

1995
- 1995-11-30 DE DE19544768A patent/DE19544768C1/de not_active Expired - Fee Related
1996
- 1996-11-08 JP JP9520104A patent/JP2000501085A/ja active Pending
- 1996-11-08 EP EP96938998A patent/EP0863759A1/de not_active Withdrawn
- 1996-11-08 WO PCT/EP1996/004906 patent/WO1997019686A1/de not_active Application Discontinuation
- 1996-11-08 HU HU9903698A patent/HUP9903698A2/hu unknown
- 1996-11-08 CA CA002238770A patent/CA2238770A1/en not_active Abandoned
1998
- 1998-05-29 NO NO982463A patent/NO982463D0/no unknown

Also Published As

Publication number	Publication date
DE19544768C1 (de)	1997-07-10
WO1997019686A1 (de)	1997-06-05
HUP9903698A2 (hu)	2000-03-28
CA2238770A1 (en)	1997-06-05
EP0863759A1 (de)	1998-09-16
NO982463L (no)	1998-05-29
NO982463D0 (no)	1998-05-29

Publication	Publication Date	Title
AU718500B2 (en)	2000-04-13	Remedies for diabetes
JP5646617B2 (ja)	2014-12-24	多発性硬化症の治療のための組成物および方法
JP2004531468A5 (de)	2009-04-02
EA000964B1 (ru)	2000-08-28	Способ лечения или предупреждения остеопороза
JP2000501085A (ja)	2000-02-02	多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用
CA2519803A1 (en)	2004-10-14	Use of erythropoietin in stroke recovery
JPH08512311A (ja)	1996-12-24	慢性疲労症候群治療用ヒ素医薬
JPH09504792A (ja)	1997-05-13	慢性関節リウマチに関する治療
CA2317577A1 (en)	1999-07-29	Methods of decreasing or preventing pain using spicamycin or derivatives thereof
CN111803487B (zh)	2022-12-02	银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途
WO2020207398A1 (zh)	2020-10-15	银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途
JPH11509213A (ja)	1999-08-17	複合治療におけるｔｎｆレセプター及びステロイドホルモン
RU2721282C2 (ru)	2020-05-18	Способ лечения рассеянного склероза (варианты)
JPH09506603A (ja)	1997-06-30	多発性硬化症治療でのペントキシフィリンの使用
CN114206329A (zh)	2022-03-18	组合疗法方法、组合物和试剂盒
JP2506307B2 (ja)	1996-06-12	生理機能活性剤
JP2001523724A (ja)	2001-11-27	運動ニューロン病および脱髄病を治療するためのシチコリン
JPH10279500A (ja)	1998-10-20	肥満症治療剤
EP2994133A1 (de)	2016-03-16	Zusammensetzungen und verfahren zur behandlung von neuronalem ischämischem reperfusionsschaden
JPS59139319A (ja)	1984-08-10	脳障害による身体機能障害治療剤
Johnson	1997	Role of interferons in demyelinating disease
CA1332222C (en)	1994-10-04	Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences
US20010046996A1 (en)	2001-11-29	Use of a compound for preparing a drug
JPH0429936A (ja)	1992-01-31	悪性脳腫瘍治療用医薬組成物
JPH0374330A (ja)	1991-03-28	脱髄疾患治療剤